Vident Investment Advisory’s Dynavax Technologies DVAX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q3
Sell
-11,576
Closed -$150K 304
2023
Q2
$150K Buy
+11,576
New +$132K 0.01% 1098
2019
Q2
Sell
-147,169
Closed -$1.08M 503
2019
Q1
$1.08M Sell
147,169
-5,552
-4% -$54.3K 0.06% 404
2018
Q4
$1.4M Buy
152,721
+4,703
+3% +$52.1K 0.08% 338
2018
Q3
$1.83M Sell
148,018
-10,492
-7% -$142K 0.07% 348
2018
Q2
$2.42M Buy
158,510
+67,096
+73% +$1.16M 0.1% 286
2018
Q1
$1.75M Buy
91,414
+25,176
+38% +$435K 0.07% 328
2017
Q4
$1.24M Sell
66,238
-84,020
-56% -$1.69M 0.06% 345
2017
Q3
$3.23M Buy
150,258
+4,553
+3% +$72K 0.17% 116
2017
Q2
$1.41M Buy
+145,705
New +$946K 0.12% 283

Other funds holding DVAX

Vident Investment Advisory's DVAX Position: Q3 2023 in Review

Vident Investment Advisory sold out of Dynavax Technologies (DVAX) in Q3 2023, closing a stake of 11,576 shares — an estimated $150K sold.

Vident Investment Advisory first reported a position in DVAX in Q2 2017 and held it in 9 quarters. The position peaked at $3.23M in Q3 2017. 225 funds tracked by Wall St. Rank hold DVAX as of Q3 2023.

  • Vident Investment Advisory reported no remaining Dynavax Technologies position as of Q3 2023 after selling out during the quarter.
  • Vident Investment Advisory sold 11,576 Dynavax Technologies shares in Q3 2023, an estimated $150K.
  • Vident Investment Advisory first reported a position in Dynavax Technologies in Q2 2017 and held it in 9 quarters.
  • Vident Investment Advisory's Dynavax Technologies position peaked at $3.23M in Q3 2017.
  • 225 funds tracked by Wall St. Rank held Dynavax Technologies as of Q3 2023.

Based on Vident Investment Advisory's 13F filing for Q3 2023.